STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
Simon Papillon‐Cavanagh, Parul Doshi, Radu Dobrin, Joseph D. Szustakowski, Alice M. Walsh
Abstract
INTRODUCTION: mutations in NSQ NSCLC. METHODS: Patients diagnosed with stage IIIB, IIIC, IVA or IVB NSQ NSCLC from a real-world data cohort from the Flatiron Health Network linked with genetic testing from Foundation Medicine were retrospectively assessed. Real-world, progression-free survival (rwPFS) and overall survival (OS) were calculated from time of initiation of first-line treatment. RESULTS: mutations and treatment on rwPFS (HR, 0.93; 95% CI 0.67 to 1.28; p=0.653) or OS (HR, 0.98; 95% CI 0.66 to 1.45; p=0.913). CONCLUSION: mutations are prognostic, not predictive, biomarkers for anti-PD-1/anti-PD-L1 therapy.
Topics & Concepts
STK11Internal medicineOncologyCohortMedicineLung cancerCancerCohort studyAdenocarcinomaKRASColorectal cancerLung Cancer Treatments and MutationsPeptidase Inhibition and AnalysisCancer Immunotherapy and Biomarkers